Anti-CMV cytotoxic T lymphocyte (Armata Pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CMV cytotoxic T lymphocyte (Armata Pharmaceuticals)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy

Mechanisms of ActionUpdating

TargetsNot applicable

Therapy Area/IndicationsCytomegalovirus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesArmata Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesArmata Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsCytomegalovirus Infections

Other Information

ATC CodeN/A